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Introduction
Preterm delivery is the most common cause of neonatal morbid-
ity and mortality [1–3]. Since preterm contractions correlate highly 
with preterm delivery, their inhibition by tocolysis constitutes a 
major element in the corresponding treatment [4]. Beta-adrenergic 
receptor agonists, nifedipine and atosiban, are the main drugs for 
the pharmacological therapy of preterm contractions [4, 5].
The usage of Bryophyllum pinnatum, a herbal medication tradi-
tionally used in anthroposophic medicine, as a tocolytic was estab-
lished in 1970 [6, 7]. Retrospective analyses revealed good effec-
tiveness and very good tolerability in patients treated with B. pin-
natum preparations [8, 9] and a matched-pairs study corroborated 
these results [10]. More recently, an observational study was per-
formed [11]. The use of B. pinnatum as a tocolytic agent is sup-
ported by experimental evidence [12]. The available evidence de-
manded prospective, randomised trials to characterise efficacy. 
Here, 2 trials are described which were initiated independently to 
fill in this knowledge gap. 
Patients and Methods
Both studies were approved by the local ethics committees (Trial I, Basel; 
Trial II, Zurich) and performed in accordance with the Declaration of Helsinki. 
All patients signed an informed consent form. In both trials, the number of re-
cruited patients was markedly lower than the numbers determined in the power 
analysis; therefore, results are presented descriptively only. B. pinnatum prepa-
rations used in both trials were manufactured by Weleda AG, Arlesheim, Swit-
zerland, according to Good Manufacturing Practice and with plant leaves pro-
vided by Weleda, Brazil (voucher specimen no. ZSS 29717 deposited at the Zu-
rich Succulent Plant Collection, Switzerland). The preparations are registered in 
Switzerland without indication and are defined based on manufacturing proce-
dures and specifications (mother tincture according to method 1.1.7. of the Eu-
ropean Pharmacopoeia). Two classes of compounds from B. pinnatum leaves 
have so far been investigated in detail, the flavonoid glycosides and the bufadi-
enolides [13].
Trial I (NCT00163579) was a prospective, randomised, double-blind, pla-
cebo-controlled, investigator-initiated clinical trial and started at Basel Wom-
en’s University Hospital (UFK). The aim of the trial was to investigate the effi-
cacy of B. pinnatum in the prophylaxis of preterm birth. The study was ap-
proved by Swiss Agency for therapeutic products (Swissmedic) and ran from 
February 2004 until April 2008. Women presenting with singleton pregnancies 
and at high risk of developing preterm contractions (e.g., prior preterm deliv-
ery, prior preterm contractions or prior cerclage) or with multiple pregnancies 
were recruited, if they did not fulfil the following exclusion criteria: age under 
18 years, Body Mass Index ? 30, foetal malformations known at the time of re-
cruitment and intrauterine growth restriction. The randomisation of the 2 
groups was performed using program Z by the hospital pharmacy and took 
place after the 26th gestational week. Study medication was B. pinnatum 33% 
tincture (33% of fresh plant with 45% ethanol w/w; final ethanol content 36% 
v/v; DEV 0.04: 1, i.e., 40 mg dried B. pinnatum matter in 1 g mother tincture). 
The hospital pharmacy of the University Hospital Basel produced the placebo 
solution (1% ferric chloride solution, similar mixture of ethanol and water). 
Pregnant women received 20 drops 5 times a day of either B. pinnatum tincture 
33% or placebo (i.e., maximal ethanol doses per day 0.96  g). In the cases in 
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which these treatments were not efficiently preventing preterm painful contrac-
tions (no additional criterion), participants received standard tocolysis with or 
without lung maturation. The main outcome was pregnancy duration. The 
power was calculated to be approximately 80% with a detectable difference of 
?10 days and a sample size of 30 (per group, for each of the 3 initial hypotheses) 
with a standard deviation of 2 weeks.
Trial II (NCT00391339 [14]) was a prospective, controlled, open-labelled 
randomised, clinical trial initiated at the University Hospital Zurich and spon-
sored by Weleda AG. The aim of this study with a parallel design was to com-
pare efficacy and safety of B. pinnatum 50% tablets and nifedipine in tocolysis. 
All study documents were approved by Swissmedic. The study ran from De-
cember 2006 until November 2009. In- and outpatients were included based on 
the following criteria: single pregnancy, gestational age < 34 weeks and 1 day, 
indication for loading treatment with nifedipine due to premature labour, 
Bishop score  < 5, negative fibronectin test, lack of vaginal bleeding, no con-
traindication for nifedipine or B. pinnatum, no drug abuse, no participation in 
another trial in the last 4  weeks. Study medication was B. pinnatum 50% as 
chewable tablets (each 350 mg tablet corresponds to 170 mg of leave press juice, 
dried down to 17 mg by mixing with lactose; 100 mg dried B. pinnatum matter 
in 1  g). Nifedipine, a standard medication at the University Hospital Zurich, 
B. pinnatum Placebo
Singletons  
(n = 8)
Multiplesc  
(n = 5)
Total
(n = 13)
Singletons  
(n = 5)
Multiplesd  
(n = 8)
Total  
(n = 13)
Age, years 30.6 ± 5.2 30.8 ± 3.6 30.7 ± 4.5 26.8 ± 6.1 29.8 ± 4.0 28.6 ± 4.9
Nicotine, n
Yes
No
2
6
0
5
2
11
0
4
0
8
0
12
Parity, n
0
1
5
3
4
1
9
4
4
1
6
2
10
3
Gravidity, n
1
2
≥ 3
4
3
1
3
1
1
7
4
2
3
0
2
5
1
2
8
1
4
Hospitalisation, n 8 5 13 5 8 13
Additional Tocolysis, n 8 5 13 5 8 13
Lung maturation, n
Yes 7 4 11 5 7 12
No 0 1 1 0 0 0
Unknown 1 0 1 0 1 1
Gestational age at study begin, weeks 30.3 ± 1.5 24.1 ± 4.4 27.9 ± 4.2 30.8 ± 1.1 26.5 ± 3.3 28.2 ± 3.4
Vaginal infection, n 4 1 5 4 3 7
Gestational age at study end, weeks 32.8 ± 1.4 32.1 ± 6.1 32.6 ± 3.1 34.6 ± 2.4 29.8 ± 5.1 31.6 ± 4.8
Treatment duration, days 18.7 ± 9.07 50.3 ± 14.6 28.2 ± 18.3 22.5 ± 3.5 24.2 ± 10.8 23.7 ± 9.0
Gestational age at delivery, weeks 36.3 ± 2.7 31.3 ± 3.9 34.4 ± 4.0 38.2 ± 2.2 31.9 ± 4.1 34.3 ± 4.6
Delivery, n
Vaginal 
Caesarean 
7
1
0
5
7
6
5
0
7
1
12
1
Preterm delivery, n 4 5 9 1 7 8
Term delivery, n 4 0 4 4 1 5
Compliance, n
Good
Partial
Unknown
7
1
0
3
0
2
10
1
2
2
1
2
5
1
2
7
2
4
Hospitalisation, days 13.5 ± 9.8 31.0 ± 24.0 20.2 ± 18.1 10.6 ± 13.6 21.1 ± 18.1 17.1 ± 16.8
Newborns’ weight, g 2736 ± 597 1481 ± 785 1538± 767 3206 ± 544 1828 ± 786 1721 ± 678
Newborns’ length, cm 47.1 ± 2.7 39.6 ± 4.6 39.7 ± 5.1 49.4 ± 1.8 43.1 ± 6.1 40.1 ± 6.2
pH arterial umbilical blood 7.25 ± 0.15 7.36 ± 0.03 7.31 ±0.01 7.25 ± 0.10 7.31 ± 0.04 7.30 ± 0.05
pH venous umbilical cord 7.36 ± 0.09 7.38 ± 0.03 7.34 ± 0.05 7.31 ± 0.11 7.37 ± 0.04 7.34 ± 0.4
Apgar score 5 min 9.4 ± 1.06 7.0 ± 2.7 8.5 ± 0.7 9.4 ± 1.34 8.3 ± 2.4 8.6 ± 1.1
NICU 0 1 (triplets) 1 (triplets) 0 3 3
aData are shown either as mean ± standard deviation or as number of patients.
bMissing values B. pinnatum group (placebo group) for gestational age at study end, n = 1 (n = 1) in the singleton subgroup and  
n = 2 (n = 1) in the multiple subgroup. Missing values for treatment duration or values excluded due to low compliance in the  
B. pinnatum group (and placebo group): singleton subgroup n = 1 (n = 3), multiple group n = 2 (n = 3).
ctwins, n = 3; triplets, n = 2. 
dtwins, n = 8.
NICU = neonatal intensive care unit.
Table 1. Baseline 
characteristics and  
outcomes of the  
pregnant women  
(n = 26) participating 
in Trial I and treated 
with B. pinnatum or 
placeboa,b
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B. pinnatumb
(n = 14)
Nifedipinec
(n = 13)
Baseline 
Gestational age, weeks 29.4 ± 3.2 27.8 ± 3.8
CTG, contractions/h 9.6 ± 5.6 7.7 ± 5.9
Bishop score 2.1 ± 1.2 1.4 ± 1.3
Haematological parameters
Leucocytes, 1E3/μl 11.7 ± 2.5 10.8 ± 2.6   
Thrombocytes, 1E3/μl 278 ± 59 251 ± 35
AST, U/l 19.7 ± 4.9 23.9 ± 4.3
ALT, U/l 18.9 ± 12.9 16.7 ± 6.5
CRP, mg/l 5.3 ± 4.8 10.1 ± 11.8
BPS, mm Hg 110 ± 10 111 ± 14
BPD, mm Hg 59 ± 11 63 ± 11
Pulse, bpm 79 ± 8 81 ± 14
At 0–1h
BPS, mm Hg 108 ± 11 104 ± 8
BPD, mm Hg 66 ± 12 58 ± 12
Pulse, bpm 80 ± 11 89 ± 13
At 4h
CTG, contractions/h 4.5 ± 4.2 3.8 ± 3.2
Bishop Score 2.1 ± 1.3 1.3 ± 0.8
BPS, mm Hg 111 ± 9 111 ± 16
BPD, mm Hg 66 ± 8 66 ± 17
Pulse, bpm 78 ± 14 87 ± 8
Adverse reactions, yes/no 0 6
Headached 0 6
Dizzinessd 0 2
Vomitingd 0 1
Study stopd 0 1
At 49h
Haematological parameters
Leucocytes, 1E3/μl 12.2 ± 3.3 11.1 ± 3.8
Thrombocytes, 1E3/μl 271 ± 54 253 ± 39
AST, U/l 20.9 ± 8.3 22.3 ± 4.9
ALT, U/l 19.1 ± 10.2 16.2 ± 5.6
CRP, mg/l 6.6 ± 5.2 8.4 ± 4.1
BPS, mm Hg 108 ± 12 107 ± 9
BPD, mm Hg 62 ± 11 63 ± 4
Pulse, bpm 85 ± 15 82 ± 8
Tocolysis after 49h
Yes 12 11
No 1 1
Puerperium
Gestational age at delivery, weeks 38.7 ± 2.1 37.4 ± 1.7
BPS, mm Hg 115 ± 8 110 ± 11
BPD, mm Hg 70 ± 8 64 ± 13
Pulse, bpm 73 ± 14.9 76 ± 10.9
Hospitalisation antepartum, days 9.4 ± 9.7 10.4 ± 20.5
Hospitalisation postpartum, days 4.6 ± 1.3 5.6± 1.2
Newborns’ weight, g 3246 ± 580 2957 ± 478
Newborns’ height, cm 49.3 ± 2.6 48.0 ± 2.8
Apgar
1’ 8.0 ± 1.0 8.2 ± 0.9
5’ 9.1 ± 0.7 9.1 ± 0.7
10’ 9.3 ± 0.5 9.3 ± 0.5
aData are shown either as mean ± standard deviation or as number of patients.
bMissing values B. pinnatum group: pulse at baseline examination, n = 3; blood pressure systolic and diastolic 
at 3rd examination, n = 1; pulse at 3rd examination, n = 2.
cMissing values nifedipine group: blood pressure at baseline examination, n = 1; pulse at baseline examina-
tion, n = 2; pulse and blood pressure at 1st examination, n = 1; CTG, Bishop score and adverse reactions at 2nd 
examination, n = 1; pulse and blood pressure at 2nd examination, n = 2; haematological parameters at 3rd ex-
amination, n = 1; pulse and blood pressure at 3rd examination, n = 2; all values at the 4th examination, n = 1.
dSeveral reactions possible.
ALT = alanine aminotransferase; AST = aspartate aminotransferase; bpm = beats per minute; BPS = blood 
pressure systolic; BPD = blood pressure diastolic; CRP = C-reactive protein; CTG = cardiotocography.
Table 2. Trial II: Outcomes in patient groups 
treated with B. pinnatum or nifedipine at different 
examination time points (including baseline)a
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was available as Nifedipin Mepha® 10 mg capsules (Mepha Pharma AG, Aesch, 
Switzerland) and Adalat CR® 30 mg and 60 mg tablets (Bayer AG, Zurich, Swit-
zerland). The hospital pharmacy managed the randomisation of the B. pinna-
tum and nifedipine groups with the program Randlist Version 1.0 (Datinf 
GmbH, Tuebingen, Germany). Patients in the B. pinnatum group were treated 
with 1 chewable tablet every 15 min during the first treatment hour, followed by 
2 chewable tablets every 6 h. Patients in the nifedipine group were given one 
Nifedipin Mepha® 10 mg capsule every 15 min during the first treatment hour. 
After 1 h and 15 min, they were given an Adalat CR® 60 mg tablet. Afterwards, 
patients received an Adalat CR® 60 mg or Adalat CR® 30 mg tablet alternately 
every 12 h over the following 48 h. The main outcome was the difference in pa-
tients’ response to tocolysis (contraction frequency had decreased, or contrac-
tion frequency had not decreased, but the Bishop score was <5) between the 2 
groups. For this one-sided equivalence test, results for the main outcome pa-
rameter with power 90% and significance level alpha = 0.05 lead to an estimated 
number of required 69 patients per study group. Thereby, a success rate of 
nifedipine of 80% and a detectable minimum success rate of 60% in the B. pin-
natum group were assumed. Because of possible dropouts, the effectively re-
quired number of patients was increased to 70 per group. 
Results
Trial I
For this section, see table 1. At study discontinuation, 26 preg-
nant women had been recruited. Duration of pregnancy was com-
parable in the groups with and without B. pinnatum. All patients 
were hospitalised and received additional tocolysis (atosiban, hexo-
prenalin, indomethacine, nifedipine and oral magnesium salt); one 
patient of the B. pinnatum group was additionally given progester-
one. In the B. pinnatum group, most patients were treated with 
hexoprenalin and nifedipine (5/13), with hexoprenalin alone (3/13) 
or with nifedipine alone (2/13). In the placebo group, most patients 
were treated with hexoprenalin alone (8/13) or with atosiban 
(2/13). No serious adverse drug reactions occurred during this 
study. In the B. pinnatum group, 1 newborn had a pathological ge-
netic analysis (Factor V Leiden thrombophilia); no perinatal deaths 
occurred.
Trial II
For this section, see table 2. The study was stopped prematurely 
when 27 patients had been recruited. Both groups were compara-
ble at baseline, except that patients of the B. pinnatum group were 
on average 2  years older at recruitment than patients from the 
nifedipine group (32.9  vs. 30.9  years). A comparable decrease in 
contraction frequency from the baseline examination to the exami-
nation after 4 h of treatment was observed in the 2 groups. The tol-
erability of the therapy was documented after 4 h as very good in 9 
cases of the B. pinnatum group (good: n = 5; moderate: n = 0) and 
in 1 case of the nifedipine group (good: n = 8; moderate: n = 3). In 
addition, after 49 h the tolerability was also very good in 9 cases of 
the B. pinnatum group (good: n = 5) and in 1 case of the nifedipine 
group (good: n = 8; moderate: n = 2; poor: n = 1). Alanine ami-
notransferase, aspartate aminotransferase and C-reactive protein 
values were comparable in the various examinations and in the 2 
groups. No serious adverse events happened during the study. 
Discussion
In the last decade, B. pinnatum began to be used at university 
institutions in Switzerland, where at present it constitutes an inher-
ent part of the standard preterm contractions treatment (see [15]). 
The relatively low evidence level on which this use of B. pinnatum 
is based, together with the lack of fully efficacious and well-toler-
ated synthetic, tocolytic agents, makes the performance of ran-
domised controlled trials urgent. Given the low number of patients 
who could be recruited in the 2 trials described here, no definitive 
conclusions on efficacy and safety are possible, although some re-
sults are promising for subsequent studies. This manuscript should 
be seen mainly as a contribution to bias reduction in clinical 
research.
Poor recruitment rate is the most common reason for trial dis-
continuation [16, 17] and should be reported and discussed. In the 
case of the present studies, the difficulties inherent in carrying out 
clinical trials with pregnant women are likely to have contributed 
to the severe delay in patient recruitment. The previous use of B. 
pinnatum preparations by several screened patients at study initia-
tion might have played a role, as well as the low budgets. Although 
trials I and II reveal the willingness of Swiss university institutions 
to investigate promising herbal products, the faced difficulties 
must be avoided in the future. For this purpose, enhanced financial 
and human resources for future randomised clinical trials are ur-
gently needed.
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